Stock Analysis·← Pickers

MANE

Veradermics, Incorporated

Veradermics, Incorporated (MANE) is currently in a range/mixed trend. RSI is at 58.9, with 1/3 trend checks passing.

Price
$123.70
2026-07-16
Trend score
1/3
Range / Mixed
RSI (14)
58.9
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

MANE with MA50 and MA200

129.7106.683.3960.2137.0302/0403/1704/2406/0407/15
MANE2026-02-042026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$106.79+15.83% vs price
MA200
Distance unavailable
RSI (14)
58.9Neutral zone
MACD Signal
BearishMomentum below signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for MANE

Veradermics, Incorporated (MANE) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $123.70, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 15.8%.

Momentum and stretch context

MANE currently has an RSI reading of 58.9, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.

What traders may watch next

This page is designed to help you quickly understand what the MANE chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Veradermics, Incorporated

Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.

Sector
Healthcare
Industry
Biotechnology
CEO
Reid Waldman
Employees
21
Market cap
$5.17B
Beta
0.77
52-week range
$32.00 – $131.24
Dividend
No
Exchange
NYSE
Country
US
IPO date
4 Feb 2026
ISIN
US9229671048
CUSIP
922967104
Company profile data from Financial Modeling Prep. MANE listed on NYSE.
Share dilution

MANE shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Dec 2024Mar 2026
Shares outstanding (latest)
37.3M
Since Dec 2024
-81.5%
Trend
Fewer shares outstanding (buybacks)
Historical shares-outstanding data from Financial Modeling Prep. MANE3 data points from Dec 2024 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about MANE

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.